MRNAInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Automated_Intelligence_Report :: MRNA
Algorithmic analysis of recent insider trading activity for MRNA reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 7 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $40.49M.
Market dynamics show a negative net capital flow of $9.45M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the landscape is fragmented. Bancel Stephane led the buying pressure, while Hoge Stephen registered the largest single offload of shares. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of MRNA.
$40.49M
USD NOMINAL VALUE7
UNIQUE C-SUITE ENTITIES2026.06.15
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>What is the overall insider sentiment for MRNA?
The short-term structural capital flow indicates a BEARISH sentiment, with a net flow of $9.45M generated by 7 active C-Suite entities.
>When was the latest SEC Form 4 filed for MRNA?
The most recent insider transaction on record was filed on 2026.06.15. InsiderAlpha monitors EDGAR filings and updates this terminal as new Form 4 documents are published.
>How many corporate insiders are active in MRNA?
Our dataset currently tracks 7 distinct insiders with reported transactions for MRNA in the active reporting window.